Skip to main content
. Author manuscript; available in PMC: 2015 Jan 4.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Aug 14;74(4):831–838. doi: 10.1007/s00280-014-2535-4

Table 2.

Population pharmacokinetic model parameters for patients receiving short and long daunorubicin infusions

Parameter Population
mean
Interindividual
variability
CL—Daunorubicin (L/h/m2) 116 (±14 %) 63.6 % ± 24.1 %
V1—Daunorubicin (L/m2) 68.1 (±24 %) 151 % ± 23 %
V2—Daunorubicin (L/m2) 128 (±25 %) 80.1 % ± 26 %
Q—Daunorubicin (L/hr/m2) 312 (±15 %) 99.0 % ± 31 %
CLm/F—Daunorubicinol (L/h/m2) 26.8 (±5.6 %) 63.6 % ± 22.6 %
Vm/F—Daunorubicinol (L/m2) 232 (±10 %) 108.6 % ± 27.9 %